Still Undiagnosed After Whole Genome Sequencing? Here is How to Solve It.

📌Summary

The Challenge: Standard Short-Read WGS (SR-WGS) resolves only 25–41% of rare disease cases, leaving 60–75% undiagnosed.

3 Key Strategies:

1. Data Re-analysis: Unlocks a 10–15% additional diagnostic yield with updated algorithms and databases (recommended every 1–2 years).
2. Trio/Pedigree Testing: Accelerates variant filtering (de novo, recessive) and avoids false positives.
3. Long-Read WGS (LR-WGS): Resolves complex structural variants (SVs)—such as large inversions, deletions, and non-coding enhancer disruptions—that short reads miss.

Latest Clinical Evidence: A 2026 Scottish Genomes Partnership study (Dutta et al., EJHG) achieved a 12.5% additional diagnostic yield in previously unsolved families using LR-WGS.

Actionable Roadmap: A negative result either points to non-genetic factors (warranting clinical tracking and potential symptom improvement) or undiagnosed genetic causes (requiring re-analysis, Trio testing, or targeted LR-WGS).

---

1. 3 core trategies to Overcome Undiagnosed Rare Diseases

① Advanced Genomic Tools: LR-WGS vs. RNAseq

Short-read sequencing reads DNA in tiny fragments (~150 bp), making it blind to complex structural re-arrangements. Two complementary advanced technologies help bridge this gap:

Long-Read WGS (LR-WGS):

• Pros: Generates continuous reads spanning thousands to millions of base pairs (kb to Mb). It effortlessly traverses large structural variants (SVs)—such as inversions, deletions, duplications, and translocations—as well as short tandem repeat (STR) expansions.
• Cons: Higher sequencing data costs and requires high-molecular-weight (HMW) DNA extraction with specialized bioinformatic pipelines.

RNA Sequencing (RNAseq):

• Pros: Directly evaluates the functional impact of DNA variants, such as aberrant gene expression or splicing errors.
• Cons: Limited if the disease-affected tissue (e.g., brain or specific internal organs) cannot be safely sampled, as gene expression is tissue-specific.

② Data Re-analysis: The Cost-Effective First Step

Before ordering new tests, re-analyzing existing SR-WGS data is the most economical first line of action.

Expected Diagnostic Yield: Re-analysis alone yields an additional 10–15% diagnostic rate.

Clinical Proof: In a recent study by Dutta et al. (2026), retrospective re-analysis using the SV-focused algorithm(SVRare) detected 100% (3 out of 3) of the pathogenic structural variants previously uncovered by LR-WGS. The variants were already present in the original raw data but were overlooked by older pipelines.

Recommended Frequency (Every 1–2 Years):

1. New Disease Gene Discoveries: 200–300 new rare disease genes are identified annually and updated in diagnostic gene panels.
2. Pipeline Advancements: Modern AI/bioinformatic tools regularly evolve to detect complex SVs and non-coding regulatory regions.
3. Re-classification of VUS: Variants of Uncertain Significance (VUS) are frequently re-classified as “Pathogenic” as global population databases expand.

③ Parent & Family Testing (Trio / Segregation Analysis)

Sequencing the patient alone (singleton) leaves tens of thousands of candidate variants. Sequencing both parents alongside the patient (Trio testing) dramatically improves accuracy:

• Instantly filters out harmless inherited background noise to isolate true de novo (newborn) mutations, autosomal recessive, or X-linked models.
• Reduces bioinformatic false positives, drastically narrowing down candidate variants.

---

2. Real-World Breakthroughs

A 2026 study published in the European Journal of Human Genetics by the Scottish Genomes Partnership (SGP) highlights the clinical power of Oxford Nanopore-based LR-WGS:

• Cohort : 24 previously undiagnosed families (74 individuals) after standard SR-WGS
• Platform : Oxford Nanopore Technologies (ONT) LR-WGS
• Diagnostic Outcome : Resolved 12.5% (3/24 families) with pathogenic or likely pathogenic structural variants

🔍 Why Was LR-WGS Essential? (3 Key Clinical Cases)

Case 1: Intellectual Disability, Microcephaly & Seizures

• Discovered Variant: A 1.4 Mb de novo inversion disrupting the AUTS2 gene.
• Why Short-Reads Missed It: Short-read pipelines focused primarily on coding single nucleotide variants (SNVs). The 1.4 Mb inversion breakpoints fell into repetitive regions that caused mapping ambiguity in short reads, whereas long reads cleanly spanned the breakpoints to reveal exons 1–2 disruption.

Case 2: Split Hand/Foot Malformation (SHFM1)

• Discovered Variant: A 5.2 Mb de novo inversion at chromosome 7q21.3.
• Why Short-Reads Missed It: The inversion did not break any protein-coding gene directly. Instead, it moved an enhancer element within DYNC1I1 far away from its target limb-development genes (DLX5/6), causing a positional regulatory effect. Short-read coding exome analyses cannot detect 3D genomic spatial rearrangements of non-coding enhancers.

Case 3: Unexplained Skeletal Dysplasia (Perthes-like Disease)

• Discovered Variant: A 59.8 kb de novo multi-exon deletion (exons 6–41) in FN1.
• Why Short-Reads/CMA Missed It: Chromosomal Microarray (CMA) flagged a deletion signal but lacked the breakpoint resolution needed to confirm pathogenicity, leaving it as a VUS. LR-WGS precisely defined the exact deletion boundaries and in-frame impact, elevating it to a definitive clinical diagnosis.

---

3. 4 Specific Criteria to Prioritize High-Cost LR-WGS

While LR-WGS offers superior diagnostic performance, it carries a higher price tag. It should be prioritized when at least one of the following four criteria is met:

① SR-WGS/WES is Negative, but a Monogenic Disease is Strongly Suspected: Clinical presentation strongly indicates a single-gene disorder, but no SNVs/indels were found.

② CMA Detected a Structural Variant, but it Remains a VUS: A deletion or duplication signal exists, but breakpoint resolution is needed to prove pathogenicity.

③ Inversions, Translocations, Enhancer Disruptions, or STR Expansions Are Suspected: Symptoms align with diseases caused by non-coding regulatory dislocation or repeat expansion disorders.

④ Parental DNA (Trio Samples) is Fully Available: Having trio samples allows instant de novo filtering across ~25,000 structural variants, maximizing diagnostic success.

---

4. Conclusion: What a ‘Negative’ Result Truly Means & Next Steps

A negative WGS report does not mean a genetic answer will never be found. It falls into one of two distinct clinical categories:

Non-Genetic Factors: Conditions caused by perinatal infections, birth trauma, autoimmune issues, or environmental factors.

• Strategy : Closely monitor the clinical trajectory. Non-genetic conditions frequently stabilize or improve significantly over time with targeted rehabilitation and supportive care.

Undiagnosed Genetic Factors: Complex structural variants, non-coding mutations, or novel genes not yet cataloged.

• Strategy : Execute a structured 3-Step Roadmap:
  Step 1: Request SR-WGS Data Re-analysis (if 1–2 years have passed).
  Step 2: Ensure Trio/Pedigree Testing is established.
  Step 3: Pursue Long-Read WGS (LR-WGS) if any of the 4 priority criteria are met.

---

❓Frequently Asked Questions (FAQ)

Q1. Why recommend data re-analysis before jumping straight to LR-WGS?

A. Cost and accessibility. Re-analysis utilizes existing data without requiring new blood draws or high sequencing fees, yielding an additional 10–15% diagnosis rate using updated bioinformatic algorithms. LR-WGS can then be reserved for cases where re-analysis remains negative.

Q2. How much does LR-WGS cost, and is it covered by health insurance?

A. Data generation for LR-WGS currently costs approximately twice as much as short-read WGS. Because it is an emerging technology, clinical utility guidelines are still being established globally, meaning it is rarely covered by standard insurance or public health reimbursement yet. Patients often access it through rare disease research programs or specialized clinical genomic centers.

Q3. Should I choose RNAseq or LR-WGS first?

A. It depends on the clinical phenotype. RNAseq is preferred when neuromuscular symptoms or splicing defects are suspected and disease-affected tissue (blood or muscle) can be safely sampled. LR-WGS is preferred when large chromosomal rearrangements, inversions, complex SVs, or short tandem repeat (STR) expansions are suspected.

Q4. What are the specific advantages of analyzing parental samples (Trio) alongside the patient?

A. While singleton testing is possible, Trio analysis provides major patient-centric benefits:

• Shortens Turnaround Time: Comparing against healthy parents instantly filters out thousands of harmless inherited variants, significantly reducing wait times for final clinical reports.
• Provides Essential Family Planning Information: Instantly determines whether a mutation is a new de novo event or inherited, providing exact recurrence risk estimates for future pregnancies.
• Prevents Secondary Testing Costs: Avoids ambiguous VUS reports that would otherwise require secondary follow-up testing for parental confirmation later on.

---